Physician profile
Catherine E Bernardini
NPI 1760421390
$1,647.74
in general payments reported to CMS, 2019-2025
26 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $165 · 2020: $29.99 · 2021: $285 · 2022: $232 · 2023: $481 · 2024: $303 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $283.02 | 2023-2024 | Veozah |
| Aspira Women'S Health INC | $255.22 | 2021 | |
| Abbvie INC. | $186.32 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $183.79 | 2023-2025 | Myfembree |
| Shield Therapeutics INC | $89.44 | 2024 | |
| Pfizer INC. | $83.19 | 2023-2024 | |
| Coopersurgical, INC. | $74.36 | 2019-2022 | |
| Organon LLC | $57.66 | 2023-2024 | Nexplanon |
| Sage Therapeutics, LLC | $42.95 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $42.30 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $40.42 | 2019 | |
| Medtronic, INC. | $39.52 | 2022-2023 | Truclear |
| Amgen INC. | $30.89 | 2019-2022 | |
| Boston Scientific Corporation | $27.58 | 2024 | Wavewriter Alpha Prime 16 |
| Meditrina | $26.86 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.74 | 2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $20.09 | 2025 | |
| Supernus Pharmaceuticals, INC. | $19.49 | 2025 | Qelbree |
| Lupin INC. | $18.80 | 2020 | |
| Duchesnay USA Incorporated | $18.48 | 2022 | |
| Myovant Sciences INC. | $16.80 | 2022 | |
| Allergan, INC. | $16.00 | 2019 | |
| Neuronetics, INC. | $14.57 | 2019 | |
| Millicent US INC | $13.55 | 2019 | |
| Minerva Surgical, INC | $11.51 | 2019 | |
| Avion Pharmaceuticals | $11.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Bernardini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.